Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON

Jefferies Financial Group Inc. purchased a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 88,440 shares of the company’s stock, valued at approximately $1,922,000. Jefferies Financial Group Inc. owned approximately 0.33% of Eton Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lumbard & Kellner LLC acquired a new position in Eton Pharmaceuticals in the 3rd quarter worth $3,831,000. GSA Capital Partners LLP acquired a new stake in shares of Eton Pharmaceuticals during the third quarter valued at about $321,000. Vanguard Group Inc. grew its stake in shares of Eton Pharmaceuticals by 2.4% during the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after acquiring an additional 31,942 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Eton Pharmaceuticals by 44.9% during the third quarter. JPMorgan Chase & Co. now owns 351,417 shares of the company’s stock worth $7,636,000 after acquiring an additional 108,837 shares during the last quarter. Finally, Navellier & Associates Inc. purchased a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $380,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $18.09 on Thursday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals, Inc. has a one year low of $11.09 and a one year high of $23.00. The company’s 50-day simple moving average is $16.26 and its 200-day simple moving average is $17.26. The stock has a market capitalization of $485.17 million, a price-to-earnings ratio of -72.36 and a beta of 1.19.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. HC Wainwright increased their price target on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen lowered Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.